MHRA Explains Entry Criteria for UK's New Innovative Medicines Pathway
‘Innovation Passport’ Will Be Gateway To Targeted Development
A new licensing route is to be introduced by the UK MHRA next year for products that meet specific criteria, such as treating life threatening conditions or rare diseases and where there is a significant patient need. At a webinar this week, an MHRA medical assessor looked at the requirements that products will have to meet to enter the new pathway.
You may also be interested in...
Companies that are in earlier stages of the drug development process will benefit most from the UK regulator's new pathway for innovative medicines.
The cancer drug is also to undergo an accelerated assessment by the European Medicines Agency.
The UK regulator, the MHRA, has published guidance on its new integrated pathway for innovative drug approvals, which it says is intended to bring together partners including health technology assessment agencies, health care bodies and patient organizations to offer “sustained collaboration” with drug developers.